Tumor Necrosis Factor α Influences Phenotypic Plasticity and Promotes Epigenetic Changes in Human Basal Forebrain Cholinergic Neuroblasts by Guarnieri, Giulia et al.
 International Journal of 
Molecular Sciences
Article
Tumor Necrosis Factor α Influences Phenotypic
Plasticity and Promotes Epigenetic Changes in
Human Basal Forebrain Cholinergic Neuroblasts
Giulia Guarnieri 1,*, Erica Sarchielli 1, Paolo Comeglio 2, Erika Herrera-Puerta 3, Irene Piaceri 4,
Benedetta Nacmias 4 , Matteo Benelli 5, Gavin Kelsey 6,7 , Mario Maggi 8, Pasquale Gallina 9,
Gabriella Barbara Vannelli 1 and Annamaria Morelli 1,*
1 Section of Human Anatomy and Histology, Department of Experimental and Clinical Medicine,
University of Florence, 50134 Florence, Italy; erica.sarchielli@unifi.it (E.S.); vannelli@unifi.it (G.B.V.)
2 Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences
“Mario Serio”, University of Florence, 50134 Florence, Italy; paolo.comeglio@unifi.it
3 Biology Group CES-EIA, CES University, Medellín 050021, Colombia; yamile.herrera@gmail.com
4 Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence,
50134 Florence, Italy; irene.piaceri@gmail.com (I.P.); benedetta.nacmias@unifi.it (B.N.)
5 Bioinformatics Unit, Hospital of Prato, Azienda USL Toscana Centro, 50122 Prato, Italy;
matteo.benelli@uslcentro.toscana.it
6 Epigenetics Programme, The Babraham Institute, Cambridge CB22 3AT, UK; gavin.kelsey@babraham.ac.uk
7 Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 1TN, UK
8 Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”,
University of Florence, 50134 Florence, Italy; mario.maggi@unifi.it
9 Neurosurgical Unit, Department of Neurosciences, Psychology, Drug Research and Child Health,
University of Florence, 50134 Florence, Italy; pgallina@unifi.it
* Correspondence: giulia.guarnieri@unifi.it (G.G.); a.morelli@unifi.it (A.M.);
Tel.: +39-3203843280 (G.G.); +39-0552758058 (A.M.)
Received: 17 July 2020; Accepted: 18 August 2020; Published: 25 August 2020


Abstract: TNFα is the main proinflammatory cytokine implicated in the pathogenesis of
neurodegenerative disorders, but it also modulates physiological functions in both the developing
and adult brain. In this study, we investigated a potential direct role of TNFα in determining
phenotypic changes of a recently established cellular model of human basal forebrain cholinergic
neuroblasts isolated from the nucleus basalis of Meynert (hfNBMs). Exposing hfNBMs to TNFα
reduced the expression of immature markers, such as nestin and β-tubulin III, and inhibited primary
cilium formation. On the contrary, TNFα increased the expression of TNFα receptor TNFR2 and
the mature neuron marker MAP2, also promoting neurite elongation. Moreover, TNFα affected
nerve growth factor receptor expression. We also found that TNFα induced the expression of
DNA-methylation enzymes and, accordingly, downregulated genes involved in neuronal development
through epigenetic mechanisms, as demonstrated by methylome analysis. In summary, TNFα showed
a dual role on hfNBMs phenotypic plasticity, exerting a negative influence on neurogenesis despite a
positive effect on differentiation, through mechanisms that remain to be elucidated. Our results help
to clarify the complexity of TNFα effects in human neurons and suggest that manipulation of TNFα
signaling could provide a potential therapeutic approach against neurodegenerative disorders.
Keywords: neuroinflammation; Alzheimer’s disease; neurogenesis; human fetal neurons;
DNA methylation; nucleus basalis of Meynert; ciliogenesis; NGF; TNFα receptors
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1. Introduction
The term neuroinflammation is currently used to indicate a cytokine-mediated inflammatory
response that originates in the central nervous system (CNS) by the regulation of different cell types,
including immune and neuronal cells, to protect the brain from local and peripheral insults. However,
when a neuroinflammatory response persists, it may trigger dangerous processes for CNS health.
During the past years, growing evidence has shown that chronic inflammatory conditions play a
crucial role in the pathogenic mechanisms underlying the onset and progression of neurodegenerative
disorders, especially those characterized by cognitive decline, such as Alzheimer’s disease (AD)
and Parkinson’s disease (PD) [1]. Epidemiological studies and research in animal models indicate
that cognitive and memory impairments are strictly linked to altered production of inflammatory
mediators [2–4]. Accordingly, anti-inflammatory drugs seem to protect against the development of
neurodegeneration and cognitive symptoms [5–7]. On the other hand, it has been demonstrated that
pro-inflammatory pathways may affect tissue organization and higher brain function during prenatal
and postnatal periods [8].
Among the pro-inflammatory mediators, tumor necrosis factor α (TNFα) represents one of the
most important pleiotropic cytokines involved in the neuroinflammatory response. Accumulating
evidence has indicated that, under physiological conditions, TNFα exerts crucial biological functions
both in the developing and adult brain but, in other conditions the chronic production of the cytokine
causes neurotoxic effects, leading to neurodegeneration [9].
Cytokines, such as TNFα can pass the placenta-fetal barrier reaching the fetal brain and
influencing its development [10]. In particular, high level of TNFα during the prenatal period has been
associated with alteration in cognitive development in the postnatal and childhood life [8]. In addition,
accumulating evidence have shown that TNFα negatively affects fetal and adult neurogenesis [11].
Indeed, in vitro studies revealed that TNFα exposure reduces the number of neuronal progenitors in
embryonic rat whole-brain neurospheres [12] and in rat as well as mouse hippocampal progenitor
cells [13–15]. Likewise, TNFα impaired neurogenesis in human striatal and hippocampal immortalized
cell lines [16].
Basal forebrain cholinergic neurons (BFCNs) are magnocellular neurons present in the medial and
ventral cerebral hemisphere and organized in distinctive cellular structures. Among these structures,
the nucleus basalis of Meynert (NBM) includes neurons that provide the major cholinergic input to
the entire neocortex, hippocampus and amygdala, thus occupying a crucial position for modulating
cognitive functions, such as attention, learning and memory [17]. The selective degeneration of BFCNs,
especially those located in the NBM, represents a pathological hallmark for AD patients [18] and has
a predictive value for cognitive deficits in PD patients [19]. An excessive production of TNFα has
been associated with cognitive decline [6]. Indeed, a role of TNFα in potentiating cell death of NBM
cholinergic neurons, possibly via retrograde axonal damage, has been demonstrated both in vitro and
in vivo in the rat [20]. However, the TNFα effects on human BFCN development and plasticity remain
to be clarified. Indeed, the mechanisms through which pro-inflammatory mediators affect human
brain structures are complex and difficult to be elucidated, especially due to the limited availability of
study models for both in vivo and in vitro investigations.
Concerning the molecular mechanisms through which TNFα could affect neuronal development
and function, several lines of evidence suggested that environmental cell-extrinsic cues, such as
cytokine signaling, may regulate differentiation plasticity of neural cells and neural circuits through
the involvement of cell-intrinsic epigenetic mechanisms [21–23]. Epigenetic modifications, particularly
DNA methylation, have been implicated in mammalian brain development and function, both during
pre-/peri-natal CNS maturation and in the adult brain [24,25]. Moreover, an altered DNA methylation
pattern has been demonstrated in neurodegenerative diseases, such as AD and PD [26], which are
typically characterized by neuroinflammation and a predominant presence of TNFα cytokine.
Interestingly, DNA methylation changes and other epigenetic mechanisms underlying TNFα-mediated
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effects have been reported in a number of cell types [27–33]. Overall, these findings suggest the
importance of analyzing epigenetic actions of TNFα in human neuronal models.
Because of the obvious limitations of study methods that can be used in living humans,
the availability of an in vitro model represents a valuable tool in this context. In this work, we took
advantage of a primary culture of cholinergic neuroblasts isolated from the human fetal NBM
(hfNBMs), which we previously characterized [34–36], in order to investigate the direct effects of TNFα
on phenotypic plasticity of human NBM cholinergic neurons. Indeed, fetal tissue is a rich source
of cells already committed toward a specific cell fate, although they retain immature features and,
therefore, are able to proliferate and fully maturate in vitro. Hence, such a model is useful for exploring
simultaneously different effects, including those related to neurogenesis and cellular plasticity, as well
as those related to more differentiated aspects. In addition, here we evaluated, for the first time,
the DNA methylation status of hfNBMs under TNFα stimulation by genome-wide analysis.
2. Results
2.1. TNFα Affects hfNBM Cell Phenotype
The phenotype of hfNBMs and their ability to respond to TNFα were confirmed as already
published [35,36]. In particular, the cholinergic phenotype of hfNBMs is shown in Figure 1 by the strong
immunopositivity to choline acetyltransferase (ChAT; Figure 1a), the enzyme essential for acetylcholine
(Ach) synthesis, and to the specific Ach vesicular transporter (VAchT; Figure 1b). Moreover, hfNBMs
express both types of TNFα receptors (TNFR1 and TNFR2), as detected by quantitative real time
RT-PCR (qRT-PCR; Figure 1c), being TNFR1 more abundant than TNFR2. In addition, as reported in
Figure 1f, we verified that 24-h exposure of TNFα (10 ng/mL) did not affect cell viability. Next, NF-κB
p65 immunolocalization was used as an indicator of TNFα-induced inflammatory response. As shown
in Figure 1d, untreated cells retained NF-κB p65 in the cytoplasm in an inactive form, with a very low
percentage of cells showing nuclear positivity (1.48 ± 0.99%). Exposing hfNBMs to 10 ng/mL TNFα for
3 h induced a significant nuclear translocation of NF-κB p65 (86.16 ± 2.03%; p < 0.0001). Accordingly,
prolonged exposure to TNFα (10 ng/mL, 24 h) significantly increased the mRNA expression of the
NF-κB p65 target gene COX2 (cyclooxygenase 2; p < 0.001; Figure 1e).
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Figure 1. TNFα affects hfNBM cell phenotype. (a,b) Representative images showing (a) ChAT and 
(b)  VAchT  expression  in  hfNBMs  as  evaluated  by  immunofluorescence  analysis  (DAPI 
counterstained nuclei,  scale bar  100  μm).  (c) Relative mRNA  expression by qRT‐PCR  analysis of 
TNFR1 and TNFR2 receptors normalized over 18S ribosomal subunit, taken as reference gene, and 
reported as mean ± SEM (n = 6). (d) Immunofluorescent analysis of NF‐κB p65 nuclear translocation 
after TNFα stimulus (10 ng/mL, 3 h)  in comparison to untreated cells (CTL; scale bar 100 μm). (e) 
Figure 1. Cont.
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Figure 1. TNFα affects hfNBM cell phenotype. (a,b) Representative images showing (a) ChAT and
(b) VAchT expression in hfNBMs as evaluated by immunofluorescence analysis (DAPI counterstained
nuclei, scale bar 100 µm). (c) Relative mRNA expression by qRT-PCR analysis of TNFR1 and TNFR2
receptors normalized over 18S ribosomal subunit, taken as reference gene, and reported as mean ± SEM
(n = 6). (d) Immunofluorescent analysis of NF-κB p65 nuclear translocation after TNFα stimulus
(10 ng/mL, 3 h) in comparison to untreated cells (CTL; scale bar 100 µm). (e) COX2 mRNA expression in
hfNBMs by qRT-PCR after TNFα stimulation (10 ng/mL, 24 h). Data are normalized over 18S ribosomal
RNA subunit and reported as percentage of untreated cells (CTL) and displayed as mean ± SEM
of three separate experiments performed in triplicate (unpaired Student’s t-test; *** p < 0.001 vs.
CTL; n = 9). (f) MTT analysis of hfNBMs treated or not (CTL) with TNFα (10 ng/mL, 24 h; n = 3).
(g) nestin, (h) β-tubulin III, (i) GFAP, (j) MAP2 and (k) TNFR2 mRNA expression in untreated (CTL)
and TNFα-treated (10 ng/mL, 24 h) hfNBMs by qRT-PCR. Data are normalized over 18S ribosomal RNA
subunit and reported as percentage of CTL and displayed as mean ±S EM of four separate experiments
performed in triplicate (unpaired Student’s t-test; *** p < 0.001, ** p < 0.01, * p < 0.05 vs. CTL; n = 12
or n = 6). (l) nestin, (m) β-tubulin III, (n) GFAP and (o) MAP2 protein expression in untreated (CTL)
and TNFα-treated (10 ng/mL, 24 h) hfNBMs by Western blot analysis. Band intensity of the specific
protein was normalized over GAPDH or β-actin signal, expressed as percentage of CTL and displayed
as mean ± SEM of three separate experiments (unpaired Student’s t-test; * p < 0.05 vs. CTL; n = 3).
As we previously reported [35], hfNBMs express high mRNA levels of the neural precursor
marker nestin, as well as the neuronal progenitor marker β-tubulin III, indicating the presence of
cells exhibiting immature features. Interestingly, as detected by qRT-PCR, exposing hfNBMs to TNFα
(10 ng/mL; 24 h) significantly decreased the mRNA expression of nestin (p < 0.001; Figure 1g), as well as
well asβ-tubulin III (p < 0.05; Figure 1h), in comparison with unstimulated cells. In addition, the mRNA
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levels of GFAP (glial fibrillary acidic protein), a specific marker for the glial lineage also previously
detected in these cells, even at low levels [35], were significantly reduced after TNFα treatment
(p < 0.001; Figure 1i). In contrast, TNFα stimulation significantly increased mRNA expression of the
mature neuron marker microtubule associate protein 2 (MAP2) (p < 0.01; Figure 1j). The effect of TNFα
on immature and mature neural/neuronal markers nestin, β-tubulin III, GFAP, and MAP2 was also
confirmed in terms of protein expression (Figure 1l–o, respectively). Interestingly, TNFα treatment
determined a one log unit increase of TNFR2 mRNA expression (p < 0.05; Figure 1k).
To further study the effect of TNFα on the phenotype of hfNBMs, we next analyzed neurite
outgrowth. Serum-starved cells were treated with 10 ng/mL TNFα for 24 h, and the presence of neurite
elongation was evaluated by immunofluorescent detection of α-tubulin, in comparison with untreated
cells. The immunofluorescent analysis showed about 18% of cells (17.46 ± 2.56%) with neurites longer
than four times the cell body in untreated cells, while the percentage was significantly increased by
TNFα treatment (28.11 ± 3.05%, p < 0.01; Figure 2a). Most notably, the mean neurite length of TNFα
stimulated cells was significantly increased, by 40% as compared to unstimulated cells (p < 0.001;
Figure 2b).
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in panel a shows the percentage of cells with neurites longer than four times the cell body calculated 
by counting ten fields per slide of three separate experiments (unpaired Student’s t‐test; ** p < 0.01 vs. 
CTL; n = 30). Bar graph  in panel b shows the ratio between neurite  length and cell body diameter 
calculated  using  ImageJ NeuronJ  plugin  in  ten  different  fields  for  each  condition,  expressed  as 
percentage of CTL and displayed as mean ± SEM of three separate experiments (unpaired Student’s 
t‐test; *** p < 0.001 vs. CTL; n = 30). 
Figure 2. TNFα increases neurite outgrowth in hfNBMs. (a,b) Representative images (left) and graph
(right) showing (a) neurite outgrowth count and (b) length by α-tubulin staining in untreated (CTL) or
TNFα-treated (10 ng/mL, 24 h) hfNBMs (DAPI counterstained nuclei, scale bar 50 µm). Bar graph in
panel a shows the percentage of cells with neurites longer than four times the cell body calculated by
counting ten fields per slide of three separate experiments (unpaired Student’s t-test; ** p < 0.01 vs. CTL;
n = 30). Bar graph in panel b sh ws the ratio between neurite length an cell body diameter calculated
using ImageJ NeuronJ plugin i ten different fields for ach condition, expressed as percentage of CTL
and displayed as me n ± SEM of three separate xperiments (unpaired Student’s t-test; *** p < 0.001 v .
CTL; = 30).
2.2. TNFα Impairs Ciliogenesis in hfNBMs
As previously reported [35], hfNBMs express a primary cilium. Immunofluorescence analysis
using the specific marker acetylated α-tubulin revealed the presence of a primary cilium in basal
conditions in about 20% of hfNBMs (Figure 3a), while TNFα exposure (10 ng/mL for 24 h) caused a
significant reduction of the percentage of cells exhibiting a primary cilium (4.29 ± 2.03%, p < 0.001;
Figure 3b), as well as a significant reduction of the primary cilium length (p < 0.001; Figure 3c).
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Moreover, qRT-PCR analysis showed that the mRNA expression of IFT88 (intraflagellar Transport 88),
an intraflagellar transporter specific for primary-cilium formation, was significantly reduced by TNFα
treatment (p < 0.05; Figure 3d). Since we previously demonstrated that nerve growth factor (NGF)
induced ciliogenesis in hfNBMs [35], we investigated whether TNFα could interfere with this effect.
Interestingly, TNFα exposure abolished the positive effect of NGF (100 ng/mL; p < 0.001 NGF vs.
untreated cells) on ciliogenesis in terms of percentage of ciliated cells (p < 0.001 vs. untreated cells and
p < 0.001 vs. NGF; Figure 3e). In addition, NGF did not change the primary cilium length either alone
or in the presence of TNFα treatment (Figure 3f).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW  7 of 27 
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Figure 3. TNFα inhibits primary cilium formation in hfNBMs. (a) Representative images showing the
primary cilium in untreated (CTL) or TNFα-treated (10 ng/mL, 24 h) hfNBMs by immunofluorescence
using the specific marker acetylated α-tubulin (DAPI counterstained nuclei; scale bars 10 µm).
(b) Number of cells with a primary cilium counted in ten different fields for each condition and
expressed as percentage of DAPI-stained (blue) total cells. Results are reported as mean ± SEM of three
separate experiments (unpaired Student’s t-test; *** p < 0.001 vs. CTL; n = 30). (c) Evaluation of the
primary cilium length performed in at least 15 cells for untreated (CTL) and TNFα-treated (10 ng/mL,
24 h) hfNBMs, using ImageJ NeuronJ plugin. Data are expressed as percentage of CTL and reported as
mean ± SEM of three separate experiments (unpaired Student’s t-test; *** p < 0.001 vs. CTL; n = 15).
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(d) IFT88 mRNA expression in untreated (CTL) and TNFα-treated (10 ng/mL, 24 h) hfNBMs by
qRT-PCR. Data are normalized over 18S ribosomal RNA subunit and reported as percentage of CTL
and displayed as mean ± SEM of four separate experiments performed in triplicate (unpaired Student’s
t-test; ** p < 0.01 vs. CTL; n = 12). (e) Number of hfNBMs with a primary cilium after NGF treatment
(100 ng/mL) in presence (NGF+TNFα) or absence (NGF) of TNFα (10 ng/mL) for 24 h. Data are reported
as percentage of variation of untreated cells (CTL) and displayed as mean ± SEM of four separate
experiments (one-way ANOVA followed by Tukey’s post hoc analysis; *** p < 0.001 vs. CTL; # p < 0.001
vs. NGF; n = 40). (f) Evaluation of the primary cilium length performed in at least 15 hfNBMs for
NGF-treated cells (100 ng/mL) in presence (NGF+TNFα) or absence (NGF) of TNFα (10 ng/mL) for
24 h. Data are calculated using ImageJ, reported as percentage of variation of untreated cells (CTL) and
displayed as mean ± SEM of three separate experiments (one-way ANOVA followed by Tukey’s post
hoc analysis; *** p < 0.001 vs. CTL; # p < 0.001 vs. NGF; n = 15). (g) (left) p75 NTR and (right) TrkA
mRNA expression in untreated (CTL) and TNFα-treated (10 ng/mL, 24 h) hfNBMs by qRT-PCR. Data are
normalized over 18S ribosomal RNA subunit and reported as percentage of CTL and displayed as mean
± SEM of three separate experiments performed in triplicate (unpaired Student’s t-test; * p < 0.05 vs.
CTL; n = 12). (h) Flow cytometric analysis for p75 NTR protein in untreated (CTL) and TNFα-treated
(10 ng/mL, 24 h) hfNBMs. Data represent the percentage of positive cells reported as mean ± SEM of
three separate experiments performed in duplicate (unpaired Student’s t-test (* p < 0.05 vs. CTL; n = 6).
(i) TrkA protein expression in untreated (CTL) and TNFα-treated (10 ng/mL, 24 h) hfNBMs by Western
blot analysis. Bands intensity are normalized over β-actin signal, expressed as percentage of CTL and
displayed as mean ± SEM of three separate experiments performed in duplicate (unpaired Student’s
t-test; *** p < 0.001 vs. CTL; n = 6).
Given the effects of TNFα in affecting NGF-induced ciliogenesis, we evaluated whether the
cytokine could affect NGF signaling. As shown in Figure 3g, TNFα exposure (10 ng/mL for 24 h)
significantly increased the mRNA expression of p75 NTR (neurotrophin Receptor p75), the low affinity
NGF receptor, but reduced expression of the high affinity NGF receptor TrkA (tropomyosin receptor
kinase A; p < 0.05 vs. untreated cells). These results were then confirmed by protein expression
analysis (Figure 3h,i). Indeed, flow cytometry experiments using specific antibodies evidenced a low
basal expression of p75 NTR (5.05 ± 4.72%), while TNFα treatment (10 ng/mL for 24 h) significantly
increased the percentage of p75 NTR-positive cells (23.13 ± 9.47%, p < 0.05; Figure 3h). On the
contrary, although no significant change was detected in terms of number of TrkA-positive cells by
flow cytometry (data not shown), Western blot analysis showed a significant reduction of TrkA protein
expression following TNFα stimulation (p < 0.001; Figure 3i).
2.3. TNFα Modulates the Expression of Enzymes Involved in DNA Methylation
To explore the role of TNFα in epigenetic mechanisms in hfNBMs, we firstly investigated the
effects of the cytokine on the expression of key enzymes involved in DNA methylation, including
DNA methyltransferases (DNMT1, DNMT3a, DNMT3b) and ten-eleven translocation enzymes (TET1,
TET2, TET3). As shown in Figure 4, TNFα treatment (10 ng/mL), at both 24- and 48-h time points,
significantly increased the mRNA expression of DNMT1 (p < 0.01 and p < 0.001, respectively; Figure 4a),
the principal maintenance DNA methyltransferase, and the de novo activity DNTMT3a (p < 0.05 and
p < 0.01, respectively; Figure 4b) mRNA expression. No significant changes were observed in mRNA
abundance of DNMT3b (Figure 4c). Regarding the demethylation enzymes, TNFα treatment resulted
in a significant decrease in both TET1 (p < 0.05 at 24 h; p < 0.01 at 48 h; Figure 4d) and TET3 (p < 0.05 at
24 h; p < 0.01 at 48 h; Figure 4f) mRNA expression at both time points, without significant changes in
TET2 mRNA levels (Figure 4e). Moreover, further analysis at the protein level confirmed the significant
increase in DNMT1 expression upon 24-h TNFα stimulation (p < 0.05; Supplementary Figure S1).
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2.4. TNFα Changes DNA Methylation of Target Regulatory Elements in hfNBMs
Based on the results indicating the effects of TNFα in regulating enzymes involved in DNA
methylation mechanisms, we hypothesized a contribution of the cytokine to mediating epigenetic
changes in hfNBMs. To determine whether TNFα affected DNA methylation status of regulatory
regions, a genome-wide DNA methylation analysis of TNFα-treated (10 ng/mL for 24 and 48 h) and
untreated hfNBMs by reduced representative bisulfite sequencing (RRBS) was performed using three
biological replicates per condition and time point. Overall methylation of the CpG sites assessed
by RRBS in cultured hfNBMs ranged from 81.8% to 84.2% and from 80.8% to 81.82% at 24 and 48 h,
respectively (Supplementary Table S3). Similarly, the global methylation profile of TNFα-treated cells
showed a range from 81.9% to 83.3% for 24 h and 81.1% to 84.4% for 48 h of treatment, but with
no significant difference compared to untreated cells. The very low rate of methylated cytosines in
non-CpG contexts (0.4–0.8% across all samples, where “C” is located in “CHH” or “CHG” regions -
H=A, T or C – Supplementary Table S3), indicates a uniformly high bisulfite conversion rate (>99%).
To investigate the DNA methylation changes under inflammatory conditions, we carried out a
more detailed analysis of specific genomic annotations, focusing on promoters, CpG islands, shores and
gene bodies, as these regions are likely to contain DNA methylation patterns important for gene
transcription. Although we observed very similar DNA methylation level in TNFα-treated and
untreated cells within all categories analyzed (average of Pearson’s correlation coefficient R=0.989 for
both time points; Supplementary Figure S2a,b), we identified 233 statistically differentially methylated
regions (DMRs; difference >10% and FDR <0.05) between treated and control hfNBMs at the 24-h
time-point (CpG islands, n = 66; shores, n = 38; promoters, n = 57; gene bodies, n = 72; Supplementary
Figure S2a), and 263 at the 48-h time point (CpG islands, n = 74; shores, n = 45; promoters, n = 68;
gene bodies, n = 76; Supplementary Figure S2b; Supplementary Table S4). In addition, looking at the
proportion of hyper- or hypo-methylation within significantly variable genomic elements, we found
that the DMRs at the 24-h time-point, tended to be equally distributed between hyper- (CpG islands:
45.45%; shores: 31.58%; promoters: 49.12%; gene bodies: 51.39%) and hypo-methylation (CpG islands:
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54.55%; shores: 68.42%; promoters: 50.88%; gene bodies: 48.61%; Figure 5a), whereas there was
an enrichment of hyper-methylation into all DMR categories (CpG islands: 66.22%; shores: 62.22%;
promoters: 61.76%; gene bodies: 69.74%) at 48 h of TNFα treatment (Figure 5b). Although only four
hypo-methylated and three hyper-methylated significant DMRs (FDR <0.05) overlapped between 24-
and 48-h time-points at the >10% change threshold (Figure 5c), we observed a concordance in the trend
of the majority of detectable DMRs (Figure 5d).
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Figure 5. Characteristics of regions differentially methylated by TNFα treatment. (a,b) Percentage
of hyper-methylation (red) and hypo-methylation (blue) of significant differentially methylated
genomic elements (CpG island, shore, promoter, gene body) at (a) 24 h and (b) 48 h of TNFα
stimulation in comparison to untreated samples. Data are expressed as percentage of total number of
significant differentially methylated regions (DMRs; FDR <0.05 logistic regression corrected for multiple
comparisons using Benjamini-Hochberg, met ylation difference ≥10%). (c) Venn diagram reporting
the number of hyper- and hypo-methyl ted significant DMRs (FDR <0.05 logistic regression corrected
for multiple comparisons using Benjamini-H chberg, methylation differenc ≥10%) detect d at 24-
and 48- hour time-points. (d) Heat map showing the difference of methylation level of TNFα-treated
hfNBMs with respect to untreated cells at 24- and 48- hour time-points. Shown are 24 h and 48 h DMRs
evaluated at CpG islands (green), shores (orange), promoters (purple) and gene bodies (pink) and
detectable in both time points.
2.5. TNFα Exposure Changes DNA Methylation of Nervous System Development-Related Genes
We next investigated whether the genes annotated to significant differentially methylated genomic
elements were involved in specific biological functions. A list of 227 genes (n = 104 hyper- and
n = 123 hypo-methylated) for DMRs at the 24-h time-point and 243 genes (n = 156 hyper- and n = 87
hypo-methylated) at the 48-h time-point was obtained. Gene ontology (GO) functional analysis
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using DAVID was performed on genes that contain differentially methylated CpG islands, shores,
promoters and gene bodies (difference >10% and FDR <0.05), all clustered in a single dataset. Functional
annotation for biological processes at 24 h indicated that genes associated with hyper-methylated
elements were enriched in developmental processes, regulation of transcription, and response to
endogenous stimuli (Figure 6a). On the other hand, genes related to hypomethylated elements were
over-represented in metabolic processes and biological regulation (Figure 6b). Interestingly, GO analysis
for the hyper-methylated 48-h gene list revealed an enrichment of genes involved in nervous system
development and regulation of transcription, suggesting the potential role of inflammation in interfering
with hfNBMs neuronal development (Figure 6c). Lastly, enrichment for the central nervous system
development category was also observed for the 48-h hypo-methylated gene list (Figure 6d).
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annotation (GO_Biological_Process) of genes associated to significant (a) hypermethylated and
(b) hypomethylated DMRs at 24 h of TNFα stimulation, and for significant (c) hyper-methylated
and (d) hypo-methylated DMRs at 48 h of TNFα stimulation in comparison to untreated cells (FDR
<0.05 logistic regression corrected for multiple comparisons using Benjamini-Hochberg, methylation
difference ≥10%). More significant terms for category are shown and data are expressed as -log10
transformed p-value of GO terms (p < 0.05). (e) CHRDL1 (left) and MEST (right) mRNA expression
in untreated (CTL) and TNFα-treated (10 ng/mL, 48 h) hfNBMs, as detected by qRT-PCR. Data are
normalized over 18S ribosomal RNA subunit and reported as percentage of CTL and displayed as mean
± SEM of three separate experiments performed in triplicate (unpaired Student’s t-test (*** p < 0.001 vs.
CTL; n = 9). (f) Bar graph showing quantitative analysis of transwell migration assay of untreated (CTL)
and TNFα-treated (10 ng/mL, 48 h) hfNBMs in absence (CTL-Serum-free) or presence (CTL-FBS; TNFα)
of 10% FBS-serum as chemoattractant. Data are evaluated in ten different field for each condition,
expressed as percentage of migrated cells and displayed as mean ± SEM of three separate experiments
(one-way ANOVA followed by Tukey’s post hoc analysis; *** p < 0.001 vs. CTL-Serum-free, ** p < 0.01
vs. CTL-FBS; n = 30).
In order to identify methylation differences of genomic elements (CpG islands, shores, promoters
and gene bodies) upon TNFα stimulation that are likely to have the greatest functional outcome,
the DMRs were filtered for a significant minimum difference of 20% and the corresponding list of genes
is reported in Table 1. A total of 25 and 46 differentially methylated genomic elements, corresponding to
nine and 16 genes, were found at the 24- and 48-h time-points, respectively. Interestingly, among variable
regions at the 48-h time-point, we found genes involved in nervous system development (MEST, GSC,
CHRDL1, HDAC10), differentiation (CHRDL1, MYLB2, HDAC10) and migration processes (MEST and
CHRDL1). On the other hand, data from the 24-h time-point revealed the presence of genes involved in
heterogeneous biological functions, such as regulation of transcription (PLAGL1 and NR0B1), protein
turnover and stabilization (HSPA12B and LAMP2) and signal transduction (KSR1 and NR0B1).
Table 1. List of genes proximal to significant DMRs with a minimum difference of 20%.
% of
Methylation
Chr AssociatedGene ID
Genomic
Element FDR CTL TNFα
TNFα
Methylation
Level vs CTL
24
-h
ou
r
ti
m
e
po
in
t
6 PLAGL1 ENSG00000118495 CpG island 5.41 × 10−41 60.49 91.14 hypermethylated
Promoter 2.06 × 10−15 60.74 91.11 hypermethylated
20 HSPA12B ENSG00000132622 CpG island 2.57 × 10−19 11.11 31.43 hypermethylated
17 KSR1 ENSG00000141068 Promoter 5.15 × 10−4 25 53.89 hypermethylated
X LAMP2 ENSG00000005893 CpG island 1.95 × 10−6 48.74 69.95 hypermethylated
Gene body 1.98 × 10−6 48.74 69.95 hypermethylated
X NR0B1 ENSG00000169297 CpG island 4.13 × 10−17 81.35 57.14 hypomethylated
Promoter 5.56 × 10−17 81.35 57.14 hypomethylated
Gene body 2.00 × 10−19 81.35 57.14 hypomethylated
1 MEGF6 ENSG00000162591 Shore 1.10 × 10−5 86.67 63.33 hypomethylated
4 SOWAHB ENSG00000186212 Shore 0.00123 65.7 43.33 hypomethylated
Gene body 1.98 × 10−6 65.7 43.33 hypomethylated
16 MSLN ENSG00000102854 Shore 1.58 × 10−7 77.55 55.61 hypomethylated
8 PVT1 ENSG00000249859 Promoter 5.15 × 10−4 50 26 hypomethylated
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Table 1. Cont.
% of
Methylation
Chr AssociatedGene ID
Genomic
Element FDR CTL TNFα
TNFα
Methylation
Level vs CTL
48
-h
ou
r
ti
m
e
po
in
t
7 MEST ENSG00000106484 CpG island 8.53 × 10−18 62.42 82.53 hypermethylated
Promoter 7.28 × 10−7 62.42 82.53 hypermethylated
14 GSC ENSG00000133937 CpG island 5.35 × 10−9 7.78 32.59 hypermethylated
Shore 1.96 × 10−9 7.78 32.59 hypermethylated
Promoter 2.16 × 10−8 7.78 32.59 hypermethylated
X CHRDL1 ENSG00000101938 CpG island 8.00 × 10−5 35 60.42 hypermethylated
Promoter 5.11 × 10−5 35 60.42 hypermethylated
X DOCK11 ENSG00000147251 CpG island 1.25 × 10−11 48.61 80.95 hypermethylated
X ARMCX2 ENSG00000184867 Promoter 7.46 × 10−5 31.27 52.26 hypermethylated
22 RPL3 ENSG00000100316 Promoter 0.00384 46.67 67.78 hypermethylated
1 TRIM62 ENSG00000116525 Gene body 3.85 × 10−8 39.17 63.89 hypermethylated
8 XKR6 ENSG00000171044 Gene body 0.00243 40.71 65.56 hypermethylated
X ARMCX2 ENSG00000184867 Promoter 5.11 × 10−5 31.27 52.26 hypermethylated
X DCAF12L2 ENSG00000198354 Promoter 1.18 × 10−35 47.37 87.68 hypermethylated
20 MYBL2 ENSG00000101057 Shore 5.09 × 10−4 71.43 46.22 hypomethylated
Promoter 5.09 × 10−4 71.43 46.22 hypomethylated
16 PRDM7 ENSG00000126856 Promoter 7.98 × 10−6 65.07 43.6 hypomethylated
21 TFF2 ENSG00000160181 Promoter 2.06 × 10−4 71.78 50.21 hypomethylated
22 HDAC10 ENSG00000100429 Promoter 1.24 × 10−4 65.33 44.76 hypomethylated
X WAS ENSG00000015285 Promoter 1.85 × 10−6 63.22 41.92 hypomethylated
14 TMEM179 ENSG00000258986 Gene body 2.08 × 10−5 70.64 49.31 hypomethylated
TNFα methylation level vs. CTL is shown in red (hypermethylated) or green (hypomethylated).
2.6. Hypermethylation of Genes Involved in Nervous System Development and Migration are Associated with a
Reduced mRNA Expression After Inflammatory Exposure
To investigate whether the TNFα-induced methylation changes could actually affect gene
expression, we performed qRT-PCR in RNA extracts from samples used for DNA methylation
studies. The analysis was performed for a set of genes annotated to significant DMRs (difference
>20% and FDR <0.05) and selected from those reported in Table 1. A significant change of mRNA
expression was found for the chordin like 1 (CHRDL1) and mesoderm specific transcript (MEST) genes,
both with TNFα-induced CpG island hyper-methylation. Indeed, the mRNA levels for these genes
were significantly reduced after 48 h of TNFα treatment (p < 0.001; Figure 6e). No statistical differences
were found for the other genes analyzed (MYLB2, PRMD7, HDAC10, DCAF12L2, PLAGL1, KSR1;
data not shown). In order to validate the increase of DNA methylation level of the CHRDL1 CpG
Island (115193-GRch37, UCSC genome) after 48-h TNFα stimulation, a methylation-sensitive restriction
qPCR analysis was performed using the EpiTect Methyl II PCR assay. Serum-starved hfNBMs were
treated with 10 ng/mL TNFα for 48 h and analyzed in comparison with untreated cells. As shown in
Supplementary Figure S3, a significant 2.5-fold increase of methylation status was detected in 48-h
TNFα treated cells in comparison with untreated cells (p < 0.05), confirming the hyper-methylation of
this region.
2.7. hfNBM Cell Migration is Inhibited by TNFα Stimulation
Since we found a significant downregulation of genes such as CHRDL1 and MEST that play
an important role in cell migration, we next analyzed, from a functional point of view, whether
TNFα affected the migratory properties of hfNBMs. Using a Boyden chamber-based migration assay,
serum-starved hfNBMs, with or without 48-h TNFα (10 ng/mL) pre-treatment, were seeded in the
upper chamber and migration was stimulated by 10% fetal bovine serum (FBS), added in the lower
well of the chamber, which is generally used for this purpose [37]. Serum-free medium in the lower
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well was used as negative control. As shown in Figure 6f, 10% FBS significantly increased the number
of migrated cells (p < 0.001 vs. FBS-free medium), while TNFα pre-treatment completely prevented
this effect.
3. Discussion
In this study, we tested the direct action of TNFα in human NBM cholinergic neurons from the fetal
brain. The overall conclusions are that the cytokine may exert pleiotropic effects in these cells, interfering
with their differentiation potential and phenotypic plasticity. Of note, epigenetic mechanisms appeared
to be implicated in these actions, as suggested by our observation of TNFα-induced changes in DNA
methylation status of target genes. Our results may contribute to improve the knowledge about the
complexity of TNFα effects in contributing to CNS diseases.
As previously described [35], hfNBMs possess features indicative of cholinergic identity, as they
express specific markers, including ChAT and VAchT, respond to the main neurotrophic factor for
this neuronal population (NGF) and are able to release Ach in the culture medium. Interestingly,
when injected in NBM-lesioned rats, hfNBMs promoted functional effects most likely because of an
improvement of the cholinergic signaling [35]. Being of fetal origin, hfNBMs also showed immature
features since they expressed precursor neuronal markers (nestin, β-tubulin III) along with a primary
cilium, which is known to be implicated in neuro-developmental processes [38]. Moreover, the cell
culture retained the same phenotype for several passages in culture. Hence, the cellular model used in
this study represents a valid tool to investigate how inflammatory insults may negatively impact on
human NBM cholinergic neurons.
It has been reported that TNFα impairs fetal and adult neurogenesis [11,14]. Indeed, in vitro
studies revealed that TNFα exposure reduces the number of neuronal progenitors in embryonic
rat whole-brain neurospheres [12] and in rat and mouse hippocampal progenitor cells [13–15].
In addition, it impairs neurogenesis in human striatal and hippocampal cell lines [16]. On the other
hand, TNFα has also been reported to induce neuronal differentiation of neural progenitor cells
(NPCs) in mice [13] and proliferation of neural stem cells (NSCs) from the subventricular zone of adult
rats [39]. However, very little is known about the effect of TNFα on cell plasticity and differentiation of
human neuronal precursors. Using human fetal cortical progenitors, Peng and colleagues demonstrated
a reduction in neuronal differentiation and an increase of gliogenesis [40]. In our study we observed
that exposing hfNBMs to TNFα determined a significant reduction of both nestin and β-tubulin III
expression, indicating a detrimental effect on the immature properties of the primary cell culture.
In addition, we found that TNFα interfered with the formation of the primary cilium in hfNBMs.
These results are consistent with similar findings described in different cellular types, such as human
fetal hypothalamic neurons [41] and mouse mesenchymal stromal cells [42] where TNFα inhibited
ciliogenesis. Primary cilia are non-motile, sensory antennas protruding 4–8 µm from the surface of
the majority of human cells, including neurons, able to mediate the cellular response to extracellular
signals growth and other stimuli [43]. Although many of primary cilium functions remain unclear,
it has been recently shown an essential role in neurogenesis, since this organelle regulates specific
neurodevelopmental signals, such as sonic hedgehog (Shh), WNT and mitogenic pathways [44].
The TNFα-mediated impairment of ciliogenesis in hfNBMs could be responsible for alterations in
neurogenic mechanisms. Indeed, recent studies have implicated primary cilia formation in the
mechanism regulating neurogenesis both during fetal development [45] and in the adult brain [46].
Furthermore, we previously described a positive effect of NGF on ciliogenesis in hfNBMs [35],
thus supporting a role of this organelle in the NGF-driven NBM neuron maturation. Since TNFα
abrogated the effect of NGF on primary cilium formation, we may hypothesize that, under inflammatory
conditions, the response of hfNBMs to NGF, and thereby their correct maturation, could be altered.
In line with this hypothesis, TNFα significantly decreased the expression of TrkA receptor, which is
known to regulate the neurotrophic effect of NGF for NBM neurons [47], thus suggesting that a possible
TNFα-mediated mechanism of action is a desensitization to NGF effects in hfNBMs. This hypothesis is
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in agreement with studies conducted in post-mortem brains of AD patients that revealed a dramatic
reduction in the expression of TrkA within NBM [48]. On the other hand, an increase of cells expressing
p75 NTR, the low affinity NGF receptor that generally mediates pro-apoptotic signals, was also
observed under TNFα stimulation in hfNBMs, thus suggesting a shift in the balance of neuroprotective
and neurotoxic pathways mediated by NGF receptors. In addition, deficits in migration, an essential
mechanism for neuronal differentiation that allows neurons to reach the proper final destination
within the brain, were observed in hfNBMs treated with TNFα. Interestingly, primary cilium has
been identified as an essential director of neuronal migration during neurogenic processes [49].
Hence, the TNFα-mediated impairment of primary cilium formation may be responsible for defects of
migration ability. Further investigations will clarify the role of primary cilia in hfNBM cell migration.
In contrast to these negative actions, our study also showed a pro-differentiation effect of TNFα
on hfNBMs, as indicated by the increased expression of the mature neuron marker MAP2 and the
promotion of neurite outgrowth after TNFα treatment. Indeed, the cytokine significantly increased the
number of neurons showing neurites and, most notably, it increased neurite length by 40% as compared
to untreated cells. Accordingly, a positive effect of the cytokine in mediating neurite outgrowth has
been observed in cultured adult sensory rat neurons [50] and in mouse organotypic brain slices [51].
This occurrence may be explained by the recruitment of compensatory mechanisms that allow the cells
to resist and survive in response to insults. In this regard, TNFα-treated hfNBMs showed a significant
decrease in the mRNA expression of the GFAP, a glial-marker also known to be expressed by early
stage neural progenitor cells [52]. This effect has already been reported in several studies [53–55]
and has been associated with glial remodeling processes to ensure neurite outgrowth [56]. Overall,
our findings suggest a dual action of TNFα-mediated inflammation on hfNBMs, showing both
beneficial and detrimental effects on the distinct components of the primary culture. In particular,
TNFα appeared to affect the neuronal plasticity of hfNBMs, acting on the immature properties of the
culture, as demonstrated by the marked reduction of nestin, β-tubulin III, and GFAP expression and
interfering with neurogenic mechanisms, including primary cilium formation as well as cell migration.
On the other hand, TNFα increased the mature marker MAP2 along with the induction of neurite
elongation, thus suggesting the ability of the cytokine to exert pro-differentiating effects on a more
mature component of the cell culture able to explicate pro-survival mechanisms. Overall, our results
may support the view that in the brain TNFα may exert both neurodegenerative and neuroprotective
roles depending on other contributing factors, which mainly include the type of recruited receptors.
Indeed, most of the negative proinflammatory functions are mediated by TNFR1, which is almost
ubiquitously expressed by brain cells and it is mainly associated with neurodegeneration, while TNFR2,
the highly regulated isoform primarily expressed at low levels by both immune cells and neurons [57],
has been implicated in protective responses to promote neuronal survival. A recent study conducted in
a mouse model of neurodegeneration demonstrated that co-administrating a TNFR1-antagonist with a
TNFR2-agonist into the magnocellular nucleus basalis protected cholinergic neurons and their cortical
projections against inflammatory insults, thus recovering memory impairing [58]. Here, we show that
hfNBMs express both types of TNFα receptors and, accordingly to the literature, TNFR1 was the most
abundant, while TNFR2 was expressed at very low levels. Interestingly, we found an increase of one
order of magnitude of TNFR2 mRNA expression in hfNBMs following TNFα stimulation, an effect
that may suggest the induction of protective mechanisms. Although further studies are needed to fully
elucidate the TNFR2-mediated neuroprotective pathways in hfNBMs, they could be associated with
the pro-differentiating effects of TNFα that we observed in terms of increased MAP2 expression and
neuritogenesis, most likely involving the mature component of the primary cell culture.
Another important finding of this study was the identification of possible epigenetic mechanisms
underlying TNFα action in hfNBMs, suggesting that TNFα may affect hfNBM maturation and
phenotype by altering the DNA methylation status. In particular, we demonstrated that TNFα
significantly increased the expression of DNMT1, the enzyme responsible for the maintenance of
DNA methylation status. Our finding is consistent with previous works in other cell types that
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indicates an increase of this enzyme along with a hypermethylation of target promoters after TNFα
stimulation [30,33,59,60]. Despite the well-known action of DNMT1 in the maintenance of DNA
methylation status, recent studies also highlighted the role of overexpressed DNMT1 in de novo
methylation [61,62]. To better investigate the occurrence of TNFα-mediated epigenetic mechanisms,
here we analyzed the genome-wide DNA methylation pattern in hfNBMs, both at basal condition and
after TNFα treatment. The global CpG methylation profile of untreated hfNBMs revealed high levels
of methylation (average of 82.5%) comparable with previous studies on fetal brain cells [24,63,64]
and no gross differences were observed with TNFα-treated samples. Although high methylation
in non-CpG sites has been identified in adult neurons and embryonic stem cells [24,65], very low
levels are detected in the fetal brain [66] and our results were consistent with these observations.
The analysis of methylation levels was focused on the comparison of different genomic regions
(CpG island, shore, promoter and gene body), mainly containing DNA methylation sites important
for regulating gene transcription, in order to obtain a more sensitive detection of small differences,
as expected during inflammatory stimulation [67]. Under the most stringent conditions (more than 20%
significant differences in methylation levels between control and TNFα stimulated cells), we identified
that 25 and 46 genomic elements with a significant methylation difference at the 24- and 48-h time
points, respectively. A tendency to hyper-methylation was observed in TNFα DMRs at the 48-h time
point, whereas at 24 h an equal distribution of hyper-methylated and hypo-methylated significant
DMRs was observed. This preferential hyper-methylation at specific genomic elements detected
only with the longer exposure to TNFα may be related to the marked increase of DNMT1. Indeed,
the overexpression of DNMT1 has been associated with selective promoter hyper-methylation and
mRNA downregulation, as demonstrated in schizophrenic patients [68], as well as in the context of
cancer biology, a pathological condition highly linked to inflammation [69]. The hypothesis that TNFα
may alter the development of hfNBMs was confirmed by a functional enrichment analysis. The GO
analysis of DMR-associated genes at 24 h of TNFα stimulation indicated an overrepresentation in
developmental processes, regulation of transcription and different signaling pathways, including
BMP signaling, which is important for neuronal development. Instead, at 48 h of inflammation
most DMRs tended to be associated with genes strictly linked to nervous system development and
regulation of transcription, suggesting the potential role of inflammation in interfering with NBM
neuron development. Moreover, quantitative gene expression analysis confirmed a significant decrease
in mRNA levels for CHRDL1 and MEST genes, which showed a significantly hyper-methylated CpG
island upon TNFα stimulus compared to untreated cells. Interestingly, both genes are implicated
in neuronal development and migration. MEST is an imprinted gene encoding an α/β hydrolase
which is expressed in both mesodermal derivatives and developing brain [70,71]. Although the role of
this enzyme in the CNS is not fully understood, it functions as a modulator of the WNT/β-catenin
pathway [72], an essential signal during brain development and in neurological diseases [73]. Moreover,
recent work indicates an essential role of MEST for the development and maintenance of different
neuronal subsets in the CNS [74,75]. Interestingly, the hyper-methylation of the MEST CpG island,
as we reported after 48 h of TNFα stimulation, could regulate the expression of miR-335, a microRNA
involved in fetal development and spatial memory as well as synaptic plasticity [76,77]. Similarly,
CHRDL1 is generally transcribed in migratory human neural progenitors and it is expressed in
neurogenic regions [78]. Interestingly, Gaughwin and colleagues indicated that a reduction of CHRDL1
transcript, due to epigenetic mechanisms, led to an increase of BMP-induced neurite outgrowth [79],
and this finding correlates well with our data on a TNFα-induced decrease of CHRDL1 transcript and
the increase of neurite outgrowth in hfNBMs. Overall, our findings strongly suggest an involvement
of neuroinflammation in modulating hfNBMs developmental processes by epigenetic mechanisms.
4. Conclusions
In conclusion, in this work, we demonstrated that TNFα-driven inflammation affects the neuronal
plasticity, maturation, and function of hfNBMs and suggest that changes in the DNA methylation
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status may be a relevant mechanism of action underlying TNF-α effects in human brain. In addition,
our results strongly support a dual role of TNFα on NBM cholinergic neurons since it may exert a
negative influence on neurogenesis despite a positive effect on differentiation, through mechanisms that
remain to be elucidated and likely depending on the type of recruited receptor. It will be interesting to
clarify whether manipulating TNFα signaling pathways dependent on its two distinct receptors could
ameliorate the deficits of cholinergic neurons, neural circuits and behavioral functions. This could
provide a potential therapeutic approach against neurodegenerative disorders.
5. Materials and Methods
5.1. hfNBM Cell Culture
All the experiments were performed using hfNBM primary cell cultures previously obtained
and characterized as already described [35] and used for experiments until passage 26. Briefly,
brain biopsies from human fetuses (two 12-week old female fetuses) were obtained from voluntary
abortions after the approval and sign of the informed consent document by the patient (ID: 20028/13
and 20029/13, released on 09/20/2013) according to the ethical guidelines of the Italian National
Institute of Health as previously reported [80]. The NBM area was dissected under a stereomicroscope
and digested with 1 mg/mL collagenase type IV (Worthington biochemical corp., Lakewood, NJ,
USA; #4188). The cell suspension was mechanically dispersed by pipetting in Coon’s modified
Ham’s F12 medium (Euroclone, Milan, Italy; #F6636) supplemented with 10% FBS (Hyclone, Logan,
UT, USA; #SH30071.02). The cell suspension obtained was cultured in dishes at 37◦ C in 5 % CO2
atmosphere and routinely checked for mycoplasma contamination by PCR assay (mycoplasma plus™
PCR primer set, Agilent technologies, Santa Clara, CA, USA; #302008). The NBM cholinergic identity
of hfNBMs was demonstrated by an extensive phenotypic and functional characterization previously
described [35]. In brief, we demonstrated that hfNBMs express the major molecular markers of the
cholinergic system, including proteins essential for Ach synthesis, transport, and hydrolysis (ChAT,
VAchT, and AchE, respectively). Moreover, hfNBMs release Ach in the culture medium and express
calbindin 1 (CALB1), along with both types of NGF receptors, TrkA and p75 NTR [35]. Indeed,
the co-expression of CALB1 with both NGF receptors is consistent with the pattern described for
cholinergic neurons in the human brain designed as “Ch4 neurons” by Mesulam and co-workers [81],
who demonstrated that these neurons correspond to the NBM. Given the fetal origin, these cells also
expressed immature markers, such as nestin, β-tubulin III, and GFAP, and retained this phenotype for
several passages in culture. Cells stored in liquid nitrogen and thawed after 1–12 months showed the
same cholinergic phenotype as before storing. Cells were treated with TNFα 10 ng/mL for 3, 24, or 48 h
to induce inflammation. NGF stimulation (100 ng/mL) were performed for 24 h in the presence or
absence of TNFα (10 ng/mL). All experiments were performed in serum-free Coon’s modified Ham’s
F12 medium (Euroclone) and cells were pre-serum-starved for 8 h, overnight or for 24 h. The use of
human fetal biopsies for research purposes was approved by the National Ethics Committee and the
local Ethics Committee for investigation in Humans of the University of Florence (Protocol Number:
678304, released on 02/01/2002).
5.2. Drugs and Antibodies
The recombinant human cytokine TNFα was purchased from Gibco (Gaithersburg, MD, USA;
#PHC3016) and reconstituted in sterile distilled water following the manufacturers’ instructions.
Human recombinant β-NGF was purchased from PeproTech Inc. (Rocky Hill, NJ, USA; #450-01) and
reconstituted in culture medium. Drugs were stored at −20 ◦C as 102 to 104 times more concentrated
stock solutions and dissolved at time of use in the medium culture to the final concentration.
Primary antibodies for immunofluorescence, Western blot, and flow cytometry analysis included
rabbit anti-ChAT polyclonal antibody (pAb; #AB143), rabbit anti-MAP2 pAb (#AB5622) from Merk
Millipore (Temecula, CA, USA), rabbit anti-VAchT pAb (#SAB4200559), mouse anti-acetylatedα-tubulin
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monoclonal antibody (mAb) from Sigma-Aldrich Corp. (St. Louis, MO, USA), mouse anti-α-tubulin
mAb (#sc-8035), mouse anti-NF-κB p65 mAb (#sc-8008), rabbit anti-TrkA pAb (H-190; #sc-14024),
mouse anti-DNMT1 mAb (H-12; #sc-271729), mouse anti-β-actin mAb (C-4; #sc-47778) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) and mouse anti-p75 NTR mAb ACP-conjugated from
Miltenyi Biotec (Bisley, Germany; ME20.4-1H4; #130-091-884). Alexa Fluor goat 488- or 568-conjugated
secondary IgG antibodies (Molecular Probes, Eugene, OR, USA; #A11029 and #A11011, respectively)
were used as appropriate for immunofluorescence and flow cytometry, whereas peroxidase-conjugated
secondary IgG anti-mouse or anti-rabbit antibodies (Santa Cruz Biotechnology; #sc-2005 and #sc-2004,
respectively) were used for Western blot analysis. ProLong Gold antifade reagent with DAPI (Invitrogen
Corp., Carlsband, CA, USA; #p36941) was used to counterstain nuclei.
5.3. Immunofluorescence
Immunofluorescence analysis was performed as already published [82]. Briefly, hfNBMs were
attached on sterile 20 × 20 mm coverslip, fixed with 2% paraformaldehyde in phosphate buffered saline
(PBS; Sigma-Aldrich Corp.; #158127) for 10 min, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich
Corp.; #T8787) in PBS for 10 min and incubated with 1% bovine serum albumin (BSA; Sigma-Aldrich
Corp.; #A2153) for 30 min at room temperature. Immunofluorescence staining was carried out using
the following primary antibodies: anti-ChAT (1:200), anti-VAchT (1:1000), anti-acetylated α-tubulin
(1:500), anti-α tubulin (1:2000) and anti-NF-κB p65 (1:100). Cells were next incubated with Alexa Fluor
488- or 568- conjugated secondary antibodies (1:200), as appropriate. Nuclei were counterstained
using ProLong Gold antifade reagent with DAPI. Negative controls were obtained avoiding primary
antibodies incubation. Neuritogenesis and primary cilium analysis were performed by counting
stained cells with neurites longer than four times the cell body and the number of cells with a
primary cilium, respectively. The neurite and cilia lengths were calculated using the ImageJ plugin
NeuronJ (ImageJ, National Institute of Health, Rockville Pike, MD, USA, http://imagej.nih.gov/ij, 1.47t).
All the measures were performed in blind by counting the stained cells in ten fields per slide of three
different experiments. The evaluation of cilium length was performed in at least 15 cells for condition.
Slides were imaged using the confocal microscopy Leica TCS SP5 (Leica Microsystems, Mannheim,
Germany) or Nikon Microphot-FXA microscope (Nikon, Tokyo, Japan).
5.4. MTT Assay
Cell viability were evaluated by MTT assay (Sigma-Aldrich Corp.) as previously reported [36].
Briefly, hfNBMs were seeded at 8 × 103 cells/well in 96 multi-well plates in culture medium
(Coon’s modified ham’s F12 medium with 10% FBS). After 24 h, hfNBMs were serum-starved
for 8 h and then stimulated with TNFα (10 ng/mL) for additional 24 h. Next, the medium was
replaced and 10 µL of MTT solution was added for 3 h at 37 ◦C. The optical density was measured
by a Multiscan FC spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) with filter at
450 nm. Cell viability was reported as a percentage of untreated cells, taken as 100% (mean ± SEM).
Each experimental point was in quadruplicate and three different experiments were performed to
obtain statistical significance.
5.5. RNA Extraction and Quantitative RT-PCR Analysis
Total RNA extraction from 2 × 105 hfNBMs was carried out using the “RNeasy Micro kit”
(Qiagen, Hilden, Germany; #74004) according to the manufacturers’ instructions. cDNA synthesis
was performed by the iScriptTM cDNA Synthesis Kit from Bio-Rad Laboratories (Hercules, CA, USA;
#1708891). Quantitative real time RT-PCR (qRT-PCR) was performed for some genes according to the
fluorescent TaqMan method, as already reported [83]. Probes and primers specific for target genes were
predeveloped assays (Life Technologies, Carlsbad, CA, USA; Supplementary Table S1). Genes were
analyzed by qRT-PCR using SsoAdvancedTM Universal SYBR®Supermix and a CFX96 Two-Color
Real-Time PCR Detection System (Bio-Rad Laboratories; #1725271) with the following thermal cycler
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conditions: 40 cycles at 95 ◦C for 15 secs and 60 ◦C for 1 min. Specific primer sequences for qRT-PCR
were custom made using sequences available at NCBI GenBank (http://www.ncbi.nlm.nih.gov; accessed
on 02/06/2018) or Ensembl Genome (http://www.ensembl.org; accessed on 02/06/2018) and are reported
in Supplementary Table S2. 18S ribosomal RNA subunit was chosen as housekeeping gene and its
expression was quantified with a predeveloped assay (Life Technologies; Hs99999901_s1) and used
during the analysis for relative quantification of the target genes. Data analysis was carried out using
the comparative threshold cycle (Ct) with 2−∆∆Ct method as already reported [84].
5.6. Western Blot Analysis
The protein extracts were obtained in RIPA lysis and extraction buffer (Thermo Fisher Scientific;
#89900) supplemented with protease inhibitors cocktails (1:100; Sigma-Aldrich Corp.; #P8340) following
the manufacturers’ instruction and quantified using Coomassie protein assay kit (Bio-Rad Laboratories;
#500-0006). Aliquots containing 20µg of protein extract were subjected to immunoblotting as previously
described [82]. Briefly, proteins were loaded on SDS-PAGE, next transferred on polyvinylidene difluoride
membranes (GE Healthcare, Little Chalfont, UK; #10600023) and blocked in 3% BSA in PBS. Specific
antibodies for protein detection were used according to the manufacturer’s suggested dilution range
as follows: anti-MAP2 (1:500) and anti-TrkA (1:1000), anti-DNMT1 (1:500), and anti-β-actin (1:10000).
Peroxidase-conjugated secondary IgG anti-mouse or anti-rabbit antibodies at 1:5000 dilution in PBS
were used, as appropriate. The proteins were revealed by the enhanced chemiluminescence system
LiteAblot extend (Euroclone; #EMP013001). Image acquisition was performed with Quantity One
software on a ChemiDoc XRS instrument (Bio-Rad Laboratories) or with Amersham Hyperfilm
(GE Healtcare, Milan, Italy) and densitometric analysis was performed by open source Java-based
ImageJ analysis software (https://imagej.net/). β-actin protein was used for protein normalization.
Three different sets of experiments were performed to obtain statistical significance.
5.7. Flow Cytometry
hfNBMs were analyzed by flow cytometry as already described [41]. Briefly, 2 × 105 hfNBMs
were resuspended in PBS supplemented with 1% FBS and, after fixation with paraformaldehyde 2%
in PBS, incubated with anti-TrkA (1:100) or anti-p75 NTR ACP-conjugated (1:20) primary antibodies.
Alexa Fluor 488 goat anti-mouse IgG (1:200) was used as secondary antibody for anti-TrkA. Negative
controls were obtained avoiding primary antibodies incubation, while autofluorescence was evaluated
in cells without antibodies. Stained cells were analyzed on a FACSCanto II instrument (BD Pharmingen,
San Diego, CA, USA). Data were analyzed using BD FACSDiva Software (BD) and FlowJo v10 (Tree Star,
Inc., Ashland, OR, USA).
5.8. DNA Extraction and Reduced Representation Bisulfite Sequencing (RRBS) Library Preparation
The whole genome methylation analysis was performed by reduced representation bisulfite
sequencing (RRBS) technique [85,86]. Genomic DNA was extracted from 5 × 105 cells from biological
triplicates of TNFα treated and untreated hfNBMs for each experimental time points (24 and 48 h) by
QIAamp®Blood Mini Kit (Qiagen; #51104) following the manufacturer’s instructions. Extracted DNA
was processed in order to perform RRBS analysis. Genomic DNA was digested with MspI restriction
enzyme (Fermentas, Vilinius, Lithuania; #ER0541), followed by end-repair and T-tailing using Klenow
Fragment 3’→5’ exo- (New England Biolabs, Beverly, MA, USA; #M0212). Unique molecular identifier
(UMIs) method was performed to ligate cytosine methylated TruSeq adapters (Illumina Inc, San Diego,
CA, USA; #ME100-0010). Ligated DNA was next purified by AMPure XP magnetic beads (Beckman
Coulter Genomics, Chaska, MN, USA; #A63882) and size selected. Bisulfite conversion, desulphonation
and purification were performed using EZ DNA methylation direct kit (Zymo research, Irvine, CA,
USA; #D5020) as per the manufacturer’s protocol. Each amplified DNA library was purified by AMPure
magnetic XP beads (Beckman Coulter Genomics) and run with high sensitivity DNA chip on a 2100
Bioanalyser (Agilent Technologies, Santa Clara, CA, USA) to assess quality and fragment sizes of RRBS
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libraries. Quantitation was performed by KAPA library quantification kit (Hofmann-La Roche, Basel,
Switzerland; #KK4824) and all RRBS libraries were sequenced by single-end (100 bp) sequencing in
one lane of the Illumina HiSeq2000 platform, as per the manufacturer’s recommendations.
5.9. DNA Methylation Data Processing
Raw sequencing data (Fastq files) were processed for quality by Fast QC program version 0.11.5
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/; Babraham Bioinformatics, Cambridge,
UK). The raw sequenced reads were initially processed to remove the first 13 bp containing the
UMI sequencing tags and next trimmed for adapters and poor-quality bases with the wrapper
script Trim Galore! version 0.4.4 (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/;
Babraham Bioinformatics). Bismark version 0.18.2 [87] was used to align trimmed reads to the human
genome (GRCh38 build) using –directional option with default parameters in single-end mode and
UmiBam (https://github.com/FelixKrueger/Umi-Grinder/blob/master/UmiBam; v0.0.1, Felix Krueger,
Babraham Bioinformatics) was used to remove duplicated reds. The UMI deduplicated reads were
processed with Bismark Methylation Extractor (Babraham Bioinformatics) using the default parameters
to generate reports with content-specific methylation information. CpG methylation calls were
analyzed and visualized by SeqMonk Mapped Sequence Data Analyser (https://www.bioinformatics.
babraham.ac.uk/projects/seqmonk/; v1.38.2, Babraham Bioinformatics) with R software implementation
(https://cran.r-project.org/bin/windows/base/; v3.5.1, The R Foundation for Statistical Computing,
Institute for Statistics and Mathematics, Wien, Austria). Three replicates for each experimental condition
were analyzed at two different time points (24 and 48 h) independently. Triplicates were used as
opposed to pool data to improve the power rather than the coverage of the analysis [88]. Whole genome
methylation analysis was performed at different genomic features as follows: CpG islands (list of
CpG islands from the SeqMonk feature annotation table; n = 22,564), shores (regions 2kb upstream
and 2kb downstream CpG islands; n = 45,128), promoters (regions 2kb upstream Transcription Start
Site of the genes from the SeqMonk feature annotation table; n = 153,967) and gene bodies (list of
gene bodies from the SeqMonk feature annotation table; n = 60,099). The SeqMonk tables refers to
Ensembl annotation. Only genomic features elements with ≥5 CpGs with read count ≥3 in all the
replicates were considered for downstream analysis. Methylation level (i.e., percentage of methylation
or beta value) was obtained by averaging the methylation level of CpG sites mapping to each element
using SeqMonk. When the methylation level was compared, DMRs within the first 30 percentile of
normalized read count (i.e., by total read count) were filtered out to obtain a reasonable CpGs measure
in all the replicates. Statistically significant differences were computed by the logistic regression
method [89] and p-values were corrected for multiple testing using Benjamini–Hochberg correction
(FDR) with ratios recalculated from normalized quantitation. Significant DMRs were identified those
showing ≥10% or ≥20% difference in methylation level and FDR <0.05. Gene annotation of significant
DMRs were performed using the “closest to gene” utility of SeqMonk (using annotation distance
cut-off of 2kb). Functional analysis of significant DMRs was performed by DAVID Bioinformatics
Resources version 6.8 (https://david.ncifcrf.gov; Frederick National Laboratory for Cancer Research,
Frederick, MD, USA)
5.10. Methylation-Sensitive Restriction Analysis
RRBS results on methylation level for CHRDL1 promoter gene were validated by methylation-
sensitive restriction qPCR analysis using the EpiTect Methyl II PCR assay (Qiagen; #335002) for
human CHRDL1 CpG Island (115193-GRch37, UCSC genome), corresponding to the region of interest.
Serum-starved hfNBMs (6 × 105) were treated with TNFα for 48 h and DNA was extracted by
QIAamp®Blood Mini Kit (Qiagen) following the manufacturer’s instructions. The DNA extracts from
control (untreated cells) and TNFα treated groups were next digested and prepared for the methylation
analysis according to the manufacturer’s instructions. The residual DNA generated by each individual
enzyme reaction was quantified by real time qPCR using a Rotor-Gene 6000 (Qiagen) with primers
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flanking the restriction sites of CHRDL1 CpG island of interest. qPCR protocol was performed following
the standard amplification conditions reported on product instructions using RT qPCR SYBR Green
MasterMix (Qiagen; #330500). In order to verify the cutting enzyme efficiency, we used SEC and DEC
assays (Qiagen; #EPHS115450-1A and #EPHS115451-1A, respectively). The values processed were
reliable only if SEC and DEC passed the quality control. Differences in DNA methylation level were
analyzed using the supplied EpiTect Methyl II PCR Microsoft Excel template. CHRDL1 methylation
analysis was performed in duplicates on three independent experiments.
5.11. Migration Assay
Cell migration was assessed using a 48-well chemotaxis chamber (Neuro Probe, Cabin John, MD,
USA) with polycarbonate membranes (pore size 8 µm; Neuro Probe; #PFB8) coated with collagen type I
(20 µg/mL, Sigma-Aldrich Corp.; #CC050). Briefly, the lower wells of the chamber were filled with
serum-free or 10% FBS culture medium to evaluate basal or induced hfNBM migration, respectively.
TNFα pre-treated (10 ng/mL for 48 h) or untreated hfNBMs (4 × 104 cells) were seeded in serum starved
condition into the upper well and incubated for 6 h at 37 ◦C in 5% CO2 atmosphere. After the incubation
period, the migrated cells in the lower side of the membrane were fixed with absolute methanol for
15 min, washed with PBS, and stained for 30 min with 10% Giemsa solution (BioOptica, Milan, Italy;
#05-12005E) in PBS. No migrated cells, in the upper part of the membrane, were removed and the filter
was mounted on a glass slide for visualization. The number of migrated hfNBMs was counted in blind
under an optical microscope (Zeiss Axioskop 20; Carl Zeiss S.p.A., Milan, Italy) in 10 fields for each
well. Each experimental point was replicated at least six times in three independent experiments.
5.12. Statistical Analysis
Data were expressed as mean ± standard error of mean (SEM). Student’s unpaired t-tests or
one-way ANOVA followed by Tukey’s post-hoc analyses for multiple comparison were performed,
as appropriate, in order to determine statistical significance which was defined as p < 0.05. Data were
analyzed using the Statistical Package for the Social Sciences (SPSS v.25.0; SPSS Inc., Chicago, IL, USA;
https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-25).
Whole genome methylation analysis were performed and visualized by SeqMonk Mapped
Sequence Data Analyser v1.38.2 (https://www.bioinformatics.babraham.ac.uk/projects/seqmonk/;
Babraham Bioinformatics) and R software (https://cran.r-project.org/bin/windows/base/; The R Foundation
for Statistical Computing). The logistic regression method [89] was used in order to determine the
statistical significance and p-values were corrected for multiple testing using Benjamini–Hochberg
correction (FDR < 0.05) with ratios recalculated from normalized quantitation.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/17/
6128/s1.
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Abbreviations
hfNBMs human fetal nucleus basalis of Meynert cells
TNFα tumor necrosis factor α
CNS central nervous system
ChAT choline acetyltransferase
VAchT vesicular acetylcholine transporter
COX2 cyclooxygenase 2
GFAP glial fibrillary acidic protein
AD Alzheimer’s disease
PD Parkinson’s disease
BFCNs basal forebrain cholinergic neurons
NBM nucleus basalis of Meynert
NGF nerve growth factor
IFT88 intraflagellar Transport 88
TrkA tropomyosin receptor kinase A
p75 NTR neurotrophin Receptor p75
CALB1 calbindin 1
qRT-PCR quantitative real time RT-PCR
PBS phosphate buffered saline
FBS fetal bovine serum
RRBS reduced representation bisulfite sequencing
UMIs unique molecular identifiers
DMRs differentially methylated regions
GO Gene Ontology
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